Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study
Main finding · Received ≥1 dose of COVID-19 vaccine; association with GD incidenceResult — go to the resultOdds ratio 1.15 95% CI .92-1.43Authors' conclusion
Our study found no association between COVID-19 vaccination and the incidence of GD.
Study context
- Population
- Adults insured by Clalit Health Services, Israel (4.7 million insured)matched case-control
- Participants
- 726 vs 1,452
- Comparison
- Graves' disease (GD) cases vs matched controls: COVID-19 vaccination
- Casesn = 726
- Controlsn = 1,452reference
- Outcome
- Association of COVID-19 vaccination (≥1 dose) with incidence of GD
Main finding
As reported in the abstract
Received ≥1 dose of COVID-19 vaccine; association with GD incidence
Odds ratio
1.15
95% CI .92-1.43
Events by group
≥1 dose of COVID-19 vaccine
OR 1.15 (95% CI .92-1.43)
Observational data: associations, not effects.
Further findings
Time from first COVID-19 vaccination to GD diagnosis (cases) or index date (controls)
Time from first COVID-19 vaccination to GD diagnosis (cases) or index date (controls)
- Not significantly different
Original publication
Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study. J Clin Endocrinol Metab. Published 10 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →